Please assess the completion status of the following clinical trial:

Trial Title: Conversion From Fast Acting Oral Opioids to Abstral®

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent obtained.~* 18 years or older, of both genders.~* Opioid tolerant patients~* Estimated frequency of BTcP 0.5-4 times a day.~Exclusion Criteria:~* Treatment with SL fentanyl within two weeks prior to screening.~* Recent or planned therapy that would alter pain or responses to analgesics.~* Treatment with monoamine oxidase inhibitor \< 14 days before or concurrent with SL fentanyl treatment.~* Significantly reduced liver and/or kidney function.~* Significant prior history of substance abuse.~* Pregnancy, breast feeding or woman of childbearing potential not using adequate birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SL Fentanyl conversion (Type: EXPERIMENTAL): * Baseline period: 7-15 episodes of breakthrough cancer pain treated with prior IR opioid medication~* Treatment period: Conversion to SL Fentanyl at a Fentanyl:Prior opioid conversion factor of 1:50 (using the estimated Morphine Sulphate Equivalent dose for the prior opioid). SL Fentanyl use was followed for 8-15 episodes of breakthrough cancer pain. SL Fentanyl dose could be titrated between episodes.

Based on this trial design, predict the completion outcome and termination type (if applicable).